ArticleProceedings of the National Academy of Sciences of the United States of America2006

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Mihaela Ginj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.